---
title: "Hangzhou Jiuyuan Genetic Biopharmaceutical Clarifies Board and Committee Structure"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270478744.md"
description: "Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced the composition of its board of directors and key committees, enhancing transparency in corporate governance. The board includes executive, non-executive, and independent directors, led by chairman Fu Hang. The announcement clarifies the roles within the Audit, Nomination, and Remuneration committees, providing investors with clearer oversight and decision-making visibility."
datetime: "2025-12-22T10:40:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270478744.md)
  - [en](https://longbridge.com/en/news/270478744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270478744.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/270478744.md) | [English](https://longbridge.com/en/news/270478744.md)


# Hangzhou Jiuyuan Genetic Biopharmaceutical Clarifies Board and Committee Structure

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Hangzhou Jiuyuan Gene Engineering Co Ltd Class H ( (HK:2566) ) has shared an announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced the current composition of its board of directors, comprising executive, non-executive and independent non-executive directors, led by chairman and general manager Fu Hang. The company has also disclosed the membership structure of its three key board committees—Audit, Nomination, and Remuneration and Appraisal—clarifying which directors serve as chairpersons and members, a move that enhances transparency in corporate governance and provides investors with clearer visibility into oversight and decision-making responsibilities at the listed biopharmaceutical firm.

**More about Hangzhou Jiuyuan Gene Engineering Co Ltd Class H**

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. is a China-based genetic biopharmaceutical company, listed in Hong Kong under stock code 2566. The company operates in the biopharmaceutical industry, focusing on genetic medicines and related therapeutic products for the healthcare market.

**Average Trading Volume:** 247,459

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$1.9B

For a thorough assessment of 2566 stock, go to TipRanks’ Stock Analysis page.

## 相關資訊與研究

- [Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances](https://longbridge.com/zh-HK/news/281090118.md)
- [Shanghai Fudan-Zhangjiang Bio-Pharmaceutical subscribes to structured deposit product under Bank of China](https://longbridge.com/zh-HK/news/281521127.md)
- [Your Genetic Wellness Partners with Senior Care Expert Lance A. Slatton to Expand Reach of Actionable Biology](https://longbridge.com/zh-HK/news/281662233.md)
- [14:09 ETSeena Magowitz Foundation and Top Chef Team Partner on YouTube Pancreatic Cancer Cooking Series](https://longbridge.com/zh-HK/news/281410037.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-HK/news/281411704.md)